Ionis Pharmaceuticals, Inc.

NasdaqGS IONS

Ionis Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 97.30%

Ionis Pharmaceuticals, Inc. Gross Profit Margin is 97.30% for the Trailing 12 Months (TTM) ending September 30, 2024, a -1.09% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Ionis Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 98.37%, a -0.21% change year over year.
Ionis Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 98.58%, a 0.34% change year over year.
Ionis Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 98.24%, a -0.73% change year over year.
Ionis Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 98.97%, a -0.58% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: IONS

Ionis Pharmaceuticals, Inc.

CEO	Dr. Brett P. Monia Ph.D.
IPO Date	May 17, 1991
Location	United States
Headquarters	2855 Gazelle Court
Employees	927
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Key trends

Past 5 years